Tag: Cambridge

Danaher wraps up $5.7bn acquisition of Abcam to bolster life sciences segment

businessnewstoday- December 7, 2023

Danaher Corporation (NYSE: DHR), a renowned global science and technology innovator, has announced the completion of its acquisition of Abcam plc (NASDAQ: ABCM), a key ... Read More

Danaher to acquire protein consumables supplier Abcam for $5.7bn

businessnewstoday- August 28, 2023

Danaher Corporation (NYSE: DHR), a global science and technology innovator, has announced a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier ... Read More

Boston mass shooting sends shockwaves, seven hospitalized amid Caribbean festival

businessnewstoday- August 26, 2023

In a horrifying turn of events that has shattered the city's festive spirit, at least seven people have been rushed to the hospital following a ... Read More

Microbiome company Vedanta Biosciences raises $68m in Series D

pallavi123- July 21, 2021

Vedanta Biosciences, a clinical-stage microbiome company founded by PureTech Health, has raised $68 million in a Series D financing round led by affiliates of Magnetar ... Read More

Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J

pharmanewsdaily- August 20, 2020

J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech ... Read More

Precision oncology company Black Diamond Therapeutics raises $85m

pharmanewsdaily- December 6, 2019

Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of ... Read More

Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators

pharmanewsdaily- November 2, 2019

Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of ... Read More

New US biotech company Twentyeight-Seven Therapeutics launched with $65m funding

pharmanewsdaily- September 9, 2018

A new US biotech company called Twentyeight-Seven Therapeutics (28-7) has been launched in Cambridge, which will focus on modulating non-coding RNA (ncRNA) biology to develop ... Read More